Choksi Laboratories Ltd (CHOKSILA) — shareholding pattern, promoter holding, financials and share price
About Choksi Laboratories Ltd (CHOKSILA)
Choksi Laboratories Ltd operates in the Healthcare Service Provider industry, within the Healthcare sector. It trades on the NSE as CHOKSILA and on the BSE under scrip code 526546. Its ISIN is INE493D01013.
Incorporated in 1982, Choksi Laboratories Ltd provides contract testing and analytical services. [1]
Choksi Laboratories Limited specializes in contract testing and analytical services, offering a wide range of consulting and laboratory solutions to various industries.
The company supports over 1000 product analyses and continually expands its service offerings. This vast range reflects a robust capability to cater to diverse industrial needs.
Listed peers in Healthcare Service Provider: Nephro Care India Ltd, Aspira Pathlab & Diagnostics Ltd, Invicta Diagnostic Ltd, Modern Diagnostic & Research Centre Ltd, Bandaram Pharma Packtech Ltd, N G Industries Ltd.
Valuation & Returns
10 Jul 2026At ₹121.9 a share on 10 Jul 2026, Choksi Laboratories Ltd (CHOKSILA) was valued at a price-to-earnings ratio of 43.1x against an industry P/E of 61.73x and a price-to-book of 3.6x on a book value of ₹33.89 per share as of Mar 2025. Solomo computes return on equity of 8.35% and return on capital employed of 11.37% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 43.1x
- Industry P/E
- 61.73x
- P/B
- 3.6x
- EPS (TTM)
- ₹2.83
- Book value / share
- ₹33.89
- ROE
- 8.35%
- ROCE
- 11.37%
- ROA
- 3.02%
- Debt / equity
- 1.24x
- Dividend yield
- 0%
- EBITDA margin
- 28.48%
- 52-week range
- ₹81.85 – ₹236.7
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Choksi Laboratories Ltd (CHOKSILA) reported revenue of ₹46.01 crore, net profit of ₹1.96 crore and earnings per share of ₹2.81. That compares with revenue of ₹41.78 crore and net profit of ₹1.52 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹12.82 crore and net profit ₹1.03 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 30.04 | 34.44 | 36.7 | 41.78 | 46.01 |
| Net profit (₹ cr) | 0.21 | 3.21 | 1.11 | 1.52 | 1.96 |
| EPS (₹) | 0.3 | 4.61 | 1.59 | 2.18 | 2.81 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 7.22% | 8.21% | 11.62% | 13.84% |
| Profit growth | 8.65% | - | 94.51% | 36.94% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 31.48% of Choksi Laboratories Ltd (CHOKSILA) (unchanged from the previous quarter), foreign institutional investors (FII) hold 7.02%. Market capitalisation was ₹85 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: Nexus Global Opportunities Fund 7.02%, Sachin Seth 3.67%, Gaurav Anand 2.87%, Emkey Commercial Company Limited 2.44%, Asc Consulting Private Limited 2.25%, Shantanu Trivedi 2.15%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 31.48% | - | 7.02% | - | 68.52% |
| Mar 2026 | 31.48% | - | 6.03% | - | 68.52% |
| Dec 2025 | 31.48% | - | 5.69% | - | 68.52% |
| Sep 2025 | 31.48% | - | 5.69% | - | 68.52% |
| Jun 2025 | 31.48% | - | 4.31% | - | 68.52% |
| Mar 2025 | 31.48% | - | 1.94% | - | 68.52% |
| Dec 2024 | 31.48% | - | - | - | 68.52% |
| Sep 2024 | 31.48% | - | - | - | 68.52% |